Investors must wait until a conference call later this week for full details, but the decision by BioCryst Pharmaceuticals Inc. and Presidio Pharmaceuticals Inc. to ditch their $101 million merger might seem almost inevitable, coming in the wake of problems for BioCryst's drug candidates in flu, hepatitis C virus (HCV) and hereditary angioedema.